jain.com

Full-stack AI platform development

Company: Nebius

Subject kind
product
Statement date
2026-08-19
Current status
verified

The claim, verbatim

Plans to develop full-stack AI platform

Source (primary)

Nebius Group (NASDAQ:NBIS) Shares Down 9.9% Following Insider Selling - MarketBeat (-, news_article)
View cached copy (2026-09-01)Live source ↗

Quote: “develop its full-stack AI platform”

How we checked this

Checked on October 10, 2026. The cited source supports every part of this claim.

The article states Nebius plans to use the financing to expand data-center capacity, develop its full-stack AI platform and purchase GPUs and other equipment.

Confirmed in the source:

What we did: Read our cached copy of the publisher (https://www.marketbeat.com/instant-alerts/nebius-group-nasdaqnbis-shares-down-99-following-insider-selling-2026-08-19/) in full (19,498 characters, retrieved September 1, 2026) and checked each assertion in the claim against it.

Additional evidence

confirms Nebius Group (NASDAQ:NBIS) Shares Down 9.9% Following Insider Selling - MarketBeat

Quote: “develop its full-stack AI platform”

View cached copy (2026-09-01)Live source ↗

confirms Nebius Group announces proposed private offering of $4.50 billion of convertible senior notes - The National Law Review

Quote: “The Company intends to use the net proceeds from the offering of the Notes to finance the continuing growth of its business, including expenditures related to the construction and build-out of its data centers, investments to develop its full-stack AI cloud, the expansion of its data center footprint and the procurement of key components (including GPUs)”

View cached copy (2026-09-12)Live source ↗

Record of changes

September 1, 2026 — stated
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
October 9, 2026 — verified
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.